Immunotherapy based on immune checkpoint blockades (ICB) is a promising treatment for aggressive cancers. However, such therapy fails in many tumors that are poorly infiltrated by cytotoxic immune cells. We found a new receptor involved in preventing recruitment of cytotoxic immune cells into tumors. Targeting this receptor represents an innovative strategy to induce tumor infiltration of immune cells, making tumors eligible for ICB-based therapy.
|Effective start/end date||1/12/19 → 31/07/20|
- FNR - Fonds National de la Recherche: €42,000.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.